Profile banner
Eric Schuur

Eric Schuur

Biotech CEO pioneering regenerative medicine and cell therapies

Palo Alto, California
hepatx
Joined August 2025
Favicon imagelinkedin.com
Favicon imagehepatx.com
Favicon imagescholar.google.com
Favicon imageresearchgate.net
Favicon imagex.com

Network

4.2K connections
🚀
Biotech Founders CEOs
🧬
Regenerative Medicine Experts
🎓
Stanford StartX Ecosystem
🤝
Biotech Business Development
⚕️
Liver Disease Specialists
⚖️
Life Science Legal IP
🏥
Mayo Clinic Collaborators

Summary

Eric Schuur is a highly experienced life science executive and scientist with over 25 years in the field. He has a proven track record of leadership in early-stage biotech companies, notably as the CEO and Co-founder of HepaTx Corporation, where he focuses on developing adult stem cell therapies for liver tissue repair. His career demonstrates a strong commitment to translating scientific advancements into clinical applications. hepatx+2
With a PhD in Experimental Pathology from UCLA and a post-doctoral fellowship at the Scripps Research Institute, Dr. Schuur possesses a deep scientific foundation. His extensive publication record on Google Scholar, covering topics from prostate cancer and estrogen receptor research to viral vectors and cell therapies, highlights his significant contributions to academic research and innovation in regenerative medicine and oncology. hepatx+1
Eric is actively involved in the broader cell and gene therapy ecosystem, holding directorial and advisory roles in organizations like StartX Med Labs Cooperative Inc., the California Life Science-CIRM Cell and Gene Therapy Working Group, and the Advanced Regenerative Manufacturing Institute. He also serves as an Adviser and Mentor for Stanford University's SPARK Program and Innovation Farm Team, demonstrating his dedication to fostering new biomedical innovations and talent. hepatx+1

Work

Education

Writing

Clinical application of induced hepatocyte-like cells produced from mesenchymal stromal cells: a literature review

January 1, 2022

Review of the clinical application of hepatocyte-like cells derived from mesenchymal stromal cells.

Favicon imagescholar.google.com

Ligand-dependent interaction of estrogen receptor-α with members of the forkhead transcription factor family

January 1, 2001

Study on the interaction of estrogen receptor-α with transcription factors.

Favicon imagescholar.google.com

Tissue specific and tumor growth supperssion by adenovirus comprising prostate specific antigen

January 1, 1999

Patent on adenoviral vectors for prostate-specific antigen-mediated tumor suppression.

Favicon imagescholar.google.com

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells

January 1, 1997

Co-authored research on an adenovirus designed to selectively target and destroy prostate cancer cells expressing prostate-specific antigen.

Favicon imagescholar.google.com

Tissue specific viral vectors

January 1, 1997

Patent on the development of viral vectors for tissue-specific gene delivery.

Favicon imagescholar.google.com

Prostate-specific antigen expression is regulated by an upstream enhancer

January 1, 1996

Research detailing the regulatory mechanisms of prostate-specific antigen expression.

Favicon imagescholar.google.com